No Prescription |
 |
 | ||
|
Daclin Clinoril |
|
| ||
No Prescription » Prescription Drugs 5 » Daclin Clinoril Sulindac is used to reduce pain swelling and joint stiffness from arthritis. It is also used to treat arthritis of the spine gouty arthritis and shoulder bursitis/tendonitis. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID).DACLIN is indicated for acute or long-term use in the treatment of the following:1.Osteoarthritis 2.Rheumatoid arthritis 3.Ankylosing spondylitis 4.Periarticular diseases such as acute painful shoulder (acute subacromial bursitis/supraspinatus tendonitis) and tenosynovitis 5.Acute gouty arthritis 6.Painful low back syndrome (low back pain commonly referred to as lumbago). Dosage and Administration:DACLIN is available for administration as yellow tablets containing 100 mg or 200 mg sulindac.DACLIN should be administered twice a day. Dosage should be adjusted to the severity of the disease. The usual daily dosage of DACLIN is 400 mg per day. However the dosage may be lowered depending on the response. Dosages above 400 mg per day are not recommended.In acute gouty arthritis therapy for 7 days is usually adequate.DACLIN when administered orally should be taken with fluids or food.Caution must be taken with dosage in the elderly and in patients with liver and/or renal impairment.The propensity of NSAIs to interact with other medicines may influence the treatment of other conditions. Buy Daclin Clinoril and other Prescription Drugs 5 products online at Medstore. Buy Online at Medstore - Click Here!
About Daclin Clinoril: Product Type: Prescription Drugs 5 Daclin ( Clinoril Generic Sulindac ) Daclin (Clinoril Generic Sulindac) Clinoril Generic Sulindac 100mg 100 tablets 100mg 200(2 x 100) tablets 100mg 400(4 x 100) tablets 200mg 100 tablets 200mg 200(2 x 100)tablets Clinoril Generic Sulindac Daclin
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
